Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients

Transplantation Proceedings

Volumn 30, Issue 2, 1998, Pages 521-

  Corry, R J ^a,b   Egidi, M F ^a   Shapiro, R ^a   Sugitani, A ^a   Gritsch, H A ^a   Jordan, M L ^a   Dodson, S F ^a   Vivas, C A ^a   Scantlebury, V P ^a   Rao, A S ^a   Fung, J J ^a   Starzl, T E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

CONFERENCE PAPER; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

DIABETES MELLITUS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; PANCREAS TRANSPLANTATION; T-LYMPHOCYTES; TACROLIMUS;

EID: 13144252184     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(97)01385-7     Document Type: Conference Paper

References (1)

1. Cony RJ, Egidi MF, Shapiro R, et al: Transplant Proc 29:642, 1997